Anthropic says Claude aided early drug work with six partners
Original title: Early progress on accelerating drug development with Claude
Reported lab results include a CAR-T design about 70% shorter and about 35,000 antibody designs.
Anthropic said its life-sciences team partnered with six drug developers and began its own discovery programs, including rare childhood muscular dystrophy. Claude was used for design, hit generation, and lead optimization, with early laboratory results described by the partners. Anthropic says the work is early and that some programs may later yield medicines.
Unconfirmed: The findings are early partner-reported lab results, not approved medicines.
- Generate reported one CAR-T design about 70% shorter and roughly 10 times more receptors.
- Divergence said Claude generated about 35,000 antibody designs in about a month.
- BigHat tested about 1,010 variants over about 10 weeks.
- Named partners include Bristol Myers Squibb, Enveda, and The Column Group.
From the original article
8 min read at anthropic.com
Anthropic’s life sciences team is working to accelerate curing disease. Over the past several months, our scientists have engaged in deep research partnerships with six organizations developing new medicines: BigHat Biosciences , Bristol Myers Squibb , Divergence Labs , Enveda , Generate Biomedicines , and The Column Group . We've also begun drug discovery efforts of our own.
By dataking · anthropic.com
A short excerpt; the article and its images belong to the publisher. Summary, key facts and assessment above are AI-written from the article and can be wrong.